Susquehanna Fundamental Investments’s Viridian Therapeutics VRDN Stock Holding History

Susquehanna Fundamental Investments’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-101,083	Closed	-$3.15M	–	693
2025 Q4	$3.15M	Hold	101,083	–	–	0.11%	191
2025 Q3	$2.18M	Sell	101,083 -10,462	-9%	-$189K	0.09%	225
2025 Q2	$1.56M	Sell	111,545 -65,621	-37%	-$891K	0.04%	382
2025 Q1	$2.39M	Buy	+177,166	New	+$3.02M	0.03%	481
2023 Q2	–	Sell	-22,777	Closed	-$579K	–	885
2023 Q1	$579K	Hold	22,777	–	–	0.01%	644
2022 Q4	$665K	Buy	22,777 +2,540	+13%	+$58.5K	0.01%	773
2022 Q3	$415K	Buy	+20,237	New	+$364K	0.01%	1070

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Susquehanna Fundamental Investments's VRDN Position: Q1 2026 in Review

Susquehanna Fundamental Investments sold out of Viridian Therapeutics (VRDN) in Q1 2026, closing a stake of 101,083 shares — an estimated $3.15M sold.

Susquehanna Fundamental Investments first reported a position in VRDN in Q3 2022 and held it in 7 quarters. The position peaked at $3.15M in Q4 2025. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

Susquehanna Fundamental Investments reported no remaining Viridian Therapeutics position as of Q1 2026 after selling out during the quarter.
Susquehanna Fundamental Investments sold 101,083 Viridian Therapeutics shares in Q1 2026, an estimated $3.15M.
Susquehanna Fundamental Investments first reported a position in Viridian Therapeutics in Q3 2022 and held it in 7 quarters.
Susquehanna Fundamental Investments's Viridian Therapeutics position peaked at $3.15M in Q4 2025.
225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on Susquehanna Fundamental Investments's 13F filing for Q1 2026, filed 15 May 2026.